Intensive Upper Limb Training in Chronic Stroke
Launched by UNIVERSITY COLLEGE, LONDON · Sep 1, 2022
Trial Information
Current as of July 21, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying two different methods of intensive upper limb rehabilitation for people who have had a stroke, to see how effective they are compared to usual care. The two methods being tested are the Queen Square Upper Limb (QSUL) program, which involves 90 hours of therapy over three weeks, and the MindPod program, which uses interactive gaming technology to help with rehabilitation. Participants will be randomly assigned to one of these two groups or a wait-list group that will receive treatment later.
To be eligible for the trial, participants should have had a first-time stroke at least six months ago and have moderate difficulty using their affected arm. They should also be able to move their thumb and at least two fingers. Throughout the study, participants will undergo assessments to track their progress, including how much they can move their arm and how well they can perform daily activities. This trial aims to gather more evidence on these rehabilitation methods and identify who might benefit most from them, which could help improve future treatments for stroke survivors.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. A first-ever unilateral stroke (ischaemic or haemorrhagic) as defined by WHO at least 6-months previously;
- • 2. Moderate upper limb impairment as defined by Fugl-Meyer Upper Extremity (Woodbury et al., 2013) score between 19-46 (to avoid ceiling and floor effects);
- • 3. Must be able to voluntarily extend the thumb and/or 2 or more fingers of the affected hand (10° or more)
- Exclusion Criteria:
- • 1. Other neurological diagnoses;
- • 2. Serious communication, cognitive and language deficits (\<7 on shortened version Montreal Cognitive Assessment or \< 34 on Cognitive assessment scale for stroke patients);
- • 3. Post-stroke frozen shoulder;
- • 4. Increased muscle tone in wrist/finger extensors (≥3 on Modified Ashworth Scale);
- • 5. Loss of passive range in any upper limb joints;
- • 6. Fatigue of \<30 on the Functional Assessment of Chronic Illness Therapy (FACIT) Fatigue Scale;
- • 7. Apraxia score of \<5 on the TULIA assessment;
- • 8. Severe shoulder pain measured by Chedoke Impairment Inventory: Stage of Shoulder Pain 1, 2, and 3;
- • 9. Vision impairment that impedes seeing the television screen
About University College, London
University College London (UCL) is a leading global research institution renowned for its commitment to advancing healthcare through innovative clinical trials. As a prominent sponsor of clinical research, UCL leverages its multidisciplinary expertise and state-of-the-art facilities to conduct rigorous investigations aimed at improving patient outcomes and addressing pressing medical challenges. The institution fosters collaboration among researchers, healthcare professionals, and industry partners, ensuring that its trials adhere to the highest ethical standards and regulatory guidelines. UCL's dedication to translating scientific discoveries into practical applications underscores its role as a vital contributor to the advancement of medical science and public health.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
London, , United Kingdom
Patients applied
Trial Officials
Nick Ward, MD
Principal Investigator
University College, London
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials